T. Nikolcheva - F Hoffmann La Roche Ltd

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 20 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

PASADENA 1-year Open-label Extension

G. Pagano, A. Reyes,A. Monnet,M. Martinec,N. Shariati,T. Simuni,K. Marek,R. Postuma,N. Pavese,F. Stocchi, K. Taylor,H. Svoboda,P. Fontoura,G. Kerchner,R. Doody,A. Bonni,T. Nikolcheva

MOVEMENT DISORDERS (2023): S44-S44

引用0浏览0引用

A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease (PADOVA): Rationale, Design, and Baseline Data

T. Nikolcheva,G. Pagano,N. Pross,T. Simuni,K. Marek,R. Postuma,N. Pavese,F. Stocchi, K. Seppi,A. Monnet,N. Shariati,L. Rutten-Jacobs,S. Zanigni,T. Kustermann, K. Taylor,D. Trundell,H. Svoboda,A. Bonni,P. Fontoura,R. Doody

MOVEMENT DISORDERS (2023): S43-S43

引用0浏览0引用

Modeling Parkinson's disease progression accounting for the effect of symptomatic treatments in the Parkinson's Progression Markers Initiative study

B. Ribba,T. Simuni,K. Marek,A. Siderowf,L. Chahine, C. Diack,A. Monnet,B. Ricci,T. Nikolcheva,G. Pagano

MOVEMENT DISORDERS (2023): S568-S569

引用0浏览0引用

Baseline Fluid Biomarkers in a Phase 2 Clinical Trial in Parkinson's Disease

T. Kustermann,G. Pagano,H. Svoboda,T. Nikolcheva, K. Taylor

MOVEMENT DISORDERS (2023): S34-S34

引用0浏览0引用

Patient perspectives on symptoms and functional impacts to inform a digital assessment of Parkinson's disease

B. Fehlmann,A. Thomann, E. Davies,J. Twiss, C. (DeMuro) Romano, D. Whalley, M. Mayorga, C. Levy,F. Lipsmeier,W. Popp,T. Kustermann,H. Svoboda,T. Nikolcheva,D. Trundell,M. Lindemann, K. Taylor

MOVEMENT DISORDERS (2023): S835-S836

引用0浏览0引用

Trial of Prasinezumab in Early-Stage Parkinson's Disease

New England journal of medicine/The New England journal of medicineno. 5 (2022): 421-432

引用101浏览0WOS引用

101

231 A Phase2 Study Evaluating Safety and Efficacy of Prasinezumab in Early Parkinson’s Disease (PASADENA)

A Pagno,J Anzures-Cabrera,K I Taylor,T Nikolcheva,W Zago,H Svoboda,R Doody,P Fontoura,D Umbricht,A Bonni

Journal of neurology, neurosurgery and psychiatryno. 6 (2022): A80.1-A80

引用0浏览0引用

Exploratory analysis of the effect of delayed-start prasinezumab on motor sign progression measured with the Roche PD Mobile Application v2: PASADENA Phase II Parts 1 and 2

K. Taylor,F. Lipsmeier,E. Volkova-Volkmar, M. Scelsi,L. Essioux,A. Monnet,B. van Lier,H. Svoboda,T. Kustermann,W. Zago,T. Nikolcheva,R. Postuma,G. Pagano,M. Lindemann

MOVEMENT DISORDERS（2022）

引用0浏览0引用

Time-to-event approach mitigates the treatment masking effect of symptomatics on MDS-UPDRS Part III

S. Zanigni,N. Shariati,T. Simuni,N. Pavese,K. Marek,R. Postuma,A. Monnet, E. Moore, A. Hahn,E. Davies,N. Pross,D. Trundell,T. Nikolcheva,G. Pagano

MOVEMENT DISORDERS（2022）

引用0浏览0引用

Investigating the use of DAT-SPECT as an enrichment biomarker to determine eligibility for the phase 2 clinical trial PASADENA

T. Kustermann,S. Holiga,S. Zanigni,H. Svoboda,T. Nikolcheva,G. Pagano,K. Taylor

MOVEMENT DISORDERS（2022）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn